NMDA receptor antibodies: A rare association in inflammatory demyelinating diseases by Ramberger, M et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
NMDA receptor antibodies: A rare association in inflammatory
demyelinating diseases
Ramberger, M; Bsteh, G; Schanda, K; Höftberger, R; Rostásy, K; Baumann, M;
Aboulenein-Djamshidian, F; Lutterotti, A; Deisenhammer, F; Berger, T; Reindl, M
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bodies to NMDAR, aquaporin-4, and myelin oligodendrocyte glycoprotein by recombinant live cell-based
immunofluorescence assays. Fifty-one patients with acute disseminated encephalomyelitis, 41 with neu-
romyelitis optica spectrum disorders, 34 with clinically isolated syndrome, and 89 with multiple sclerosis
(MS) were included. Due to a known association of NMDAR antibodies with seizures and behavioral
symptoms, patients with those clinical manifestations were preferentially included and are therefore over-
represented in our cohort. Nine patients with NMDAR encephalitis, 94 patients with other neurologic
diseases, and 48 healthy individuals were used as controls. RESULTS NMDAR antibodies were found
in all 9 patients with NMDAR encephalitis but in only 1 of 215 (0.5%) patients with inflammatory
demyelination and in none of the controls. This patient had relapsing-remitting MS with NMDAR anti-
bodies present at disease onset, with an increase in NMDAR antibody titer with the onset of psychiatric
symptoms and cognitive deficits. CONCLUSION In demyelinating disorders, NMDAR antibodies are
uncommon, even in those with symptoms seen in NMDAR encephalitis.
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NMDA receptor antibodies
A rare association in inflammatory demyelinating diseases
ABSTRACT
Objectives: To analyze the frequency of NMDA receptor (NMDAR) antibodies in patients with var-
ious inflammatory demyelinating diseases of the CNS and to determine their clinical correlates.
Methods: Retrospective case-control study from 2005 to 2014 with the detection of serum IgG
antibodies to NMDAR, aquaporin-4, and myelin oligodendrocyte glycoprotein by recombinant live
cell-based immunofluorescence assays. Fifty-one patients with acute disseminated encephalo-
myelitis, 41 with neuromyelitis optica spectrum disorders, 34 with clinically isolated syndrome,
and 89 with multiple sclerosis (MS) were included. Due to a known association of NMDAR anti-
bodies with seizures and behavioral symptoms, patients with those clinical manifestations were
preferentially included and are therefore overrepresented in our cohort. Nine patients with
NMDAR encephalitis, 94 patients with other neurologic diseases, and 48 healthy individuals were
used as controls.
Results: NMDAR antibodies were found in all 9 patients with NMDAR encephalitis but in only 1 of
215 (0.5%) patients with inflammatory demyelination and in none of the controls. This patient
had relapsing-remitting MS with NMDAR antibodies present at disease onset, with an increase
in NMDAR antibody titer with the onset of psychiatric symptoms and cognitive deficits.
Conclusion: In demyelinating disorders, NMDAR antibodies are uncommon, even in those with
symptoms seen in NMDAR encephalitis. Neurol Neuroimmunol Neuroinflamm 2015;2:e141; doi:
10.1212/NXI.0000000000000141
GLOSSARY
ADEM 5 acute disseminated encephalomyelitis; AQP4 5 aquaporin-4; CBA 5 cell-based assay; CIS 5 clinically isolated
syndrome; IHC 5 immunohistochemistry; MOG 5 myelin oligodendrocyte glycoprotein; MS 5 multiple sclerosis; NMDAR 5
NMDA receptor; NMOSD 5 neuromyelitis optica spectrum disorder; ON 5 optic neuritis.
NMDA receptor (NMDAR) encephalitis is characterized by the presence of IgG autoantibodies
against NMDAR in serum and CSF and affects mainly pediatric and young adult female pa-
tients. The first symptoms are frequently psychiatric, followed by seizures, dyskinesias, memory
deficits, and speech problems, often leading to autonomic instabilities.1 Autoantibodies against
NMDAR are also found in cases of CNS demyelinating diseases such as acute disseminated
encephalomyelitis (ADEM),2 optic neuritis (ON),2 neuromyelitis optica spectrum disorders
(NMOSDs),3 or multiple sclerosis (MS).4 Recent data point to a possible association of
NMDAR antibodies with demyelination in some patients, particularly when IgG antibodies
against glial surface antigens aquaporin-4 (AQP4) or myelin oligodendrocyte glycoprotein
(MOG) are present.5
This is a unique study to systematically investigate the seroprevalence of NMDAR antibodies
in patients with CNS demyelinating diseases. We retrospectively screened a cohort of patients
with demyelinating diseases for IgG antibodies against NMDAR, AQP4, and MOG.
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METHODS Patients and controls. Serum samples for this
retrospective case-control study were collected in the Clinical
Department of Neurology Innsbruck between 2005 and 2014
and stored at 280°C until use. All patients fulfilled diagnostic
criteria as described below.
Serum samples from 366 individuals were included: 51 pa-
tients with ADEM, 41 patients with NMOSD, 34 patients with
clinically isolated syndrome (CIS), and 89 patients with MS.
Nine patients with NMDAR encephalitis, 94 patients with other
neurologic diseases, and 48 healthy individuals were included as
controls. Most of the patients have previously been included in
a study on NMDAR antibody assay validation6 and in other
studies on MOG and/or AQP4 antibodies.7,8 NMOSDs were
diagnosed as described by Wingerchuk et al. in 2007, ADEM
was diagnosed according to the criteria of the International Pedi-
atric MS Study Group, and MS and CIS were diagnosed accord-
ing to the 2005 revisions to the McDonald criteria, as previously
described.6–8 Diagnosis of NMDAR encephalitis was based on
clinical assessment (e.g., new onset of neuropsychiatric symp-
toms) and demonstration of antibodies in serum or CSF, as rec-
ommended recently.9 The relative frequency of symptoms
suggestive of NMDAR encephalitis was selectively increased in
our cohort of patients with demyelinating diseases (figure).
Standard protocol approvals, registrations, and patient
consents. The present study was approved by the ethical com-
mittee of Innsbruck Medical University (study numbers
AM3041A and AM4059). All patients or their legal representa-
tives gave written informed consent to the study protocol.
Live cell-based assays for antibody detection. For the detec-
tion of autoantibodies against NMDAR, AQP4, and MOG we
used live HEK293A cells transfected with the respective comple-
mentary DNA, as described previously.6,7 The following cutoff
values were used: $1:20 for NMDAR antibodies, $1:160 for
MOG antibodies, and $1:20 for AQP4 antibodies.
To prove the specificity of antibody binding, serum samples
were preincubated with HEK293A cells expressing NMDAR or
nontransfected HEK293A.
One CSF sample was tested for NMDAR antibodies as
described above, except CSF was applied undiluted but supple-
mented with MK-801 (Sigma-Aldrich, St. Louis, MO) and further
diluted (1:2, 1:4, etc.) in washing buffer containing MK-801.
NMDAR antibody testing with fixed cell-based assay (CBA)
and rat brain immunohistochemistry (IHC) was done as
described recently.9
RESULTS Demographic data and the NMDAR,
MOG, and AQP4 antibody seroprevalence of all pa-
tients and controls are shown in the table.
Serum NMDAR antibodies were present in 9/9
(100%) patients with NMDAR encephalitis, in only
1/89 (1%) patients with MS, and in none of the other
cases. CSF positivity of NMDAR antibodies was con-
firmed in all patients with NMDAR encephalitis by
fixed CBA and/or tissue IHC. CSF from the patient
with MS with low titer (1:20) serum NMDAR anti-
bodies at disease onset was negative for NMDAR
antibodies in our live CBA but positive in the fixed
CBA and IHC. In contrast, serum was negative in
the fixed CBA despite being positive in live CBA
and weakly positive in IHC.
At the age of 23, this woman presented with par-
esthesia of the left hand. MRI showed multiple MS-
typical T2 lesions, and investigation of CSF showed
the presence of oligoclonal bands and 15 cells/mL.
The patient was diagnosed with MS, and complete
remission was observed after treatment with high-
dose methylprednisolone. Three months later, ON
coincided with a clear increase in T2 lesions on
MRI, and she was again treated with methylprednis-
olone followed by complete remission. However,
ON reoccurred 3 years after disease onset, and the
patient had residual visual deficit despite methylpred-
nisolone treatment. The patient repeatedly declined
Figure Overview of patients with demyelinating diseases, presence of clinical
symptoms frequently associated with NMDAR encephalitis, and
antibody status
We included 215 patients with demyelinating CNS disorders. Of these, 81 presented with
seizures and/or behavioral symptoms whereas 134 did not. As expected, all 9 patients with
NMDA receptor (NMDAR) encephalitis presented with seizures and/or behavioral symptoms.
Ab5 antibody; ADEM5 acute disseminated encephalomyelitis; AQP45 aquaporin-4; CIS5
clinically isolated syndrome; HC 5 healthy controls; MOG 5 myelin oligodendrocyte glyco-
protein; MS5multiple sclerosis; NMDAR-E5 NMDAR encephalitis; NMOSD5 neuromyelitis
optica spectrum disorder; OND 5 other neurologic diseases.
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disease-modifying therapy. Nine months later she
gave birth to a healthy child. Three months postpar-
tum, at the age of 26, the patient presented with
psychiatric (dysphoria, logorrhea) and cognitive (dys-
calculia, frontal executive disorder, psychomotor
slowing) symptoms. MRI showed dramatic progres-
sion of T2 lesion load and serum was positive for low
titer antinuclear antibodies.
Absorption of patient serum with NMDAR-
transfected cells abolished the NMDAR-specific
signal in the live CBA, whereas incubation with non-
transfected cells did not, proving the specificity of
antibodies against NMDAR. Antibodies against
MOG or AQP4 were absent at any time point. Before
the patient could be treated for an autoimmune cause
of the psychiatric symptoms, she was transferred to an
outside psychiatric hospital and no further clinical
data were available.
Demographic, clinical, and antibody data of all pa-
tients with demyelinating CNS disorders with seiz-
ures and/or behavioral symptoms, which are the
major initial symptoms of NMDAR encephalitis,
are shown in the figure.
DISCUSSION Overall, we found serum NMDAR
antibodies in 1 of 215 patients with CNS demyelin-
ating diseases, suggesting that the frequency of those
autoantibodies is very low (,1%). Although a low
false-positive rate of IgG NMDAR antibodies was
reported recently,10 in our study serum IgG
NMDAR antibodies were only present in patients
with symptoms suggestive of NMDAR encephalitis.
The major limitation of our study was the small
number of available CSF samples, which could have
possibly yielded a higher number of NMDAR
antibody–positive patients with demyelinating dis-
eases when using suitable testing methods.
As demonstrated here, live CBAmight be more sen-
sitive for detecting low titer serumNMDAR antibodies
but not for testing CSF samples, as currently used.
The disease course of the 1 patient with MS
and NMDAR antibodies was initially typical for
relapsing-remitting MS with residual visual deficits
after the second episode of ON. Because analysis of
NMDAR antibodies was done retrospectively, the
occurrence of antibodies during the first episode of
demyelination was not known at that time point.
CSF was positive for NMDAR antibodies at disease
onset, in line with studies suggesting CSF to be more
sensitive than serum.1,9 With the onset of psychiatric
and cognitive symptoms, serum NMDAR antibody
titers increased. Unfortunately, CSF was not available
from the second time point.
This case demonstrates that NMDAR autoantibod-
ies can be linked with demyelination, which has been
shown in a recent study investigating a cohort of 691
patients with NMDAR encephalitis, identifying a sub-
group of patients with demyelinating episodes.5
Most reported cases (18/23) of demyelinating syn-
dromes overlapping with the presence of NMDAR
antibodies were positive for at least 1 antibody associ-
ated with demyelination, namely antibodies against
MOG or AQP4.5 In our case, those antibodies were
not found. Of note, NMDAR encephalitis–related
symptoms occurred 3 months after the patient gave
birth to a healthy child, paralleling a recently
described case,4 although our case showed a less severe
disease course.
We found NMDAR antibodies to be rare in
demyelinating diseases, even when focusing on
patients with symptoms suggestive of NMDAR
encephalitis. In the case described here, the presence
of NMDAR antibodies preceded the occurrence
of symptoms associated with NMDAR encephalitis.
Thus, serum NMDAR antibodies could have
diagnostic value for an overlapping NMDAR
encephalitis–related disease course in patients with
demyelinating diseases.
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Table Demographic data and prevalence of antibodies in patients with
demyelinating diseases and controls
n Females, n (%) Median age, y (range)
Serum IgG antibodies, n (%)
NMDAR MOG AQP4
ADEM 51 26 (51) 7 (2–52) 0 (0) 26 (51) 0 (0)
NMOSD 41 34 (83) 48 (3–81) 0 (0) 2 (5) 36 (88)
CIS 34 19 (56) 15 (4–51) 0 (0) 4 (12) 0 (0)
MS 89 57 (64) 41 (12–71) 1 (1) 1 (1) 0 (0)
NMDAR-E 9 6 (67) 18 (5–34) 9 (100) 0 (0) 0 (0)
OND 94 35 (37) 16 (1–89) 0 (0) 1 (1) 0 (0)
HC 48 40 (83) 43 (21–68) 0 (0) 0 (0) 0 (0)
Abbreviations: ADEM 5 acute disseminated encephalomyelitis; AQP45 aquaporin-4; CIS 5
clinically isolated syndrome; HC 5 healthy controls; MOG 5 myelin oligodendrocyte glyco-
protein; MS 5 multiple sclerosis; NMDAR-E 5 NMDA receptor encephalitis; NMOSD 5 neu-
romyelitis optica spectrum disorder; OND 5 other neurologic diseases.
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